TDC
KZR

Thompson Davis & Co’s Kezar Life Sciences KZR Stock Holding History

Thompson Davis & Co’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$6K Sell
30
-73
-71% -$12.7K 0.01% 540
2018
Q2 		$18K Buy
+103
New +$18K 0.04% 331

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Thompson Davis & Co's KZR Position: Q3 2018 in Review

Thompson Davis & Co reduced its Kezar Life Sciences (KZR) stake by 71% in Q3 2018, selling an estimated $12.7K and leaving 30 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #540.

Thompson Davis & Co first reported a position in KZR in Q2 2018 and has held it in 2 quarters since. The position peaked at $18K in Q2 2018. 37 funds tracked by Wall St. Rank hold KZR as of Q3 2018.

  • Thompson Davis & Co held 30 shares of Kezar Life Sciences worth $6K as of Q3 2018.
  • Thompson Davis & Co sold 73 Kezar Life Sciences shares in Q3 2018, an estimated $12.7K.
  • Kezar Life Sciences made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #540 holding.
  • Thompson Davis & Co first reported a position in Kezar Life Sciences in Q2 2018 and has held it in 2 quarters since.
  • Thompson Davis & Co's Kezar Life Sciences position peaked at $18K in Q2 2018.
  • 37 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.